Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837814 | 0.94 | HTR2A (0.35) | HTR2ACYP2A6PYCR1SIRT2SLC6A2 | |
| SCHEMBL5795845 | 0.81 | CYP1A2 (0.38) | HTR2APYCR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2710461 | 0.80 | HTR2A (0.40) | HTR2A | |
| SCHEMBL28795633 | 0.77 | CYP2A6 (0.42) | HTR2ACYP2A6PYCR1SLC6A2SLC6A4 | |
| SCHEMBL6632793 | 0.76 | HTR2A (0.38) | HTR2ACYP2A6PYCR1SLC6A2SLC6A4 | |
| SCHEMBL6173982 | 0.76 | PYCR1 (0.39) | HTR2ACYP2A6PYCR1SLC6A2SLC6A4 | |
| SCHEMBL28849818 | 0.72 | ESR1 (0.37) | HTR2APYCR1ALOX5CYP1A2 | |
| SCHEMBL15486101 | 0.70 | HTR2A (0.40) | HTR2ACYP2A6PYCR1SLC6A2SLC6A4 | |
| SCHEMBL3645610 | 0.70 | HTR2A (0.40) | HTR2ACYP2A6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22042217 | 0.67 | HRH1 (0.44) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432700-B1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7078420-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-6977267-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040259897-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1432700-A4 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1432700-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2004-01-15 | — | — | US | disclosed |
| WO-2003029245-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259897-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | HTR2A 692/4885CYP2A6 369/4885PYCR1 2874/4885 |
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | HTR2A 692/4885CYP2A6 369/4885PYCR1 2874/4885 |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | HTR2A 695/4885CYP2A6 369/4885PYCR1 2795/4885 |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, ITGA4 | HTR2A 930/4885CYP2A6 405/4885PYCR1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.